- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03363139
T790M Mutation Testing in Blood by Different Methodologies
"T790M Mutation Testing in Blood by Different Methodologies"_RING Project
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Three blood samples per patient will be collected once at the time of progression, assessed by CT Scans according to RECIST criteria v.1.1 and before the patients start a new treatment The blood samples (5-10 mL each) will be collected in one Cell-Free DNA BCT Streck® and 2 PTT EDTA K2 (BECTON DICKINSON) collection tubes.
All samples will be labeled properly with the patient identification number and date of extraction. These samples will be stored and distributed through the 3 participating laboratories until completion of all the analyses, according to the flowchart in Figure 1. These samples will be registered in the samples collection of the Institute of Health Carlos III Registry. These samples will be kept in each participant laboratory after the completion of the RING study and the patient will be informed of that in the patient information sheet and informed consent.
cfDNA will be extracted using as starting volume 1 ml of plasma with a Maxwell® RSC instrument (Promega), using the Maxwell® RSC cfDNA Plasma Kit (MR), as specified by the manufacturer or with a Qiasymphony instrument (Qiagen company). Additionally, for BEAMing analysis, 3 ml of plasma will be used for cfDNA isolation using the the QIAamp® Circulating Nucleic Acid Kit (Qiagen company), following the manufacturer instructions.
Circulating free DNA from peripheral blood sample is an adequate source for T790M resistance mutation testing. However, comparison across different platforms has been scarcely reported. Discordant results for EGFR biomarker testing could impact patient management.
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
-
Alicante, Spanien
- H. Gen. Universitario de Alicante
-
Barcelona, Spanien, 08028
- Instituto Universitario Dexeus
-
Barcelona, Spanien, 08041
- Hospital de la Santa Creu i Sant Pau
-
Burgos, Spanien, 09006
- Hospital Universitario de Burgos
-
Ciudad Real, Spanien, 13005
- Hospital Universitario de Ciudad Real
-
Girona, Spanien, 17007
- ICO Girona -H. Dr. Josep Trueta
-
Granada, Spanien, 18012
- Hospital Clínico San Cecilio
-
Jaén, Spanien, 23007
- Complejo Hospitalario de Jaén
-
León, Spanien, 24071
- Complejo Asistencial Universitario de León
-
Lugo, Spanien, 27003
- Hospital Lucus Agustí
-
Madrid, Spanien, 28046
- Hospital La Paz
-
Madrid, Spanien, 28035
- H.U. Puerta de Hierro
-
Madrid, Spanien, 28050
- Hospital Universitario Sanchinarro
-
Murcia, Spanien, 30120
- Hospital Clinico Universitario Virgen de la Arrixaca
-
Málaga, Spanien, 29010
- H. Carlos Haya
-
Sevilla, Spanien, 41013
- Hospital Virgen del Rocío
-
Valencia, Spanien, 46026
- Hospital La Fe
-
Valencia, Spanien, 46010
- Hospital Clínico Universitario de Valencia
-
Valencia, Spanien
- H. Gen. Univ. Valencia
-
Valencia, Spanien
- Hospital Arnau de Vilanova
-
Ávila, Spanien, 05004
- Hospital Nuestra Senora de Sonsoles
-
-
A Coruña
-
Santiago De Compostela, A Coruña, Spanien, 15706
- Complejo Hospitalario Universitario de Santiago
-
-
Alicante
-
Alcoy, Alicante, Spanien, 03804
- Hospital Virgen de los Lirios
-
Elche, Alicante, Spanien, 03203
- Hospital General Universitario de Elche
-
-
Asturias
-
Oviedo, Asturias, Spanien
- Hospital Central de Asturias
-
-
Gran Canaria
-
Las Palmas de Gran Canaria, Gran Canaria, Spanien, 35016
- Complejo Hospitalario Universitario Insular de Gran Canaria
-
-
Madrid
-
Alcalá De Henares, Madrid, Spanien, 28805
- Hospital Principe de Asturias
-
Leganés, Madrid, Spanien, 28911
- Hospital Severo Ochoa
-
-
Mallorca
-
Palma de Mallorca, Mallorca, Spanien, 07014
- H. Son Espases
-
-
Navarra
-
Pamplona, Navarra, Spanien, 31008
- Complejo Hospitalario de Navarra
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Patients diagnosed with EGFR mutant, stage IIIB and IV non small cell lung cancer and who have progressed assessed by CT Scans according to RECIST criteria v.1.1 to first or second generation EGFR tyrosine kinase inhibitors (TKIs) (e.g. gefitinib, erlotinib, afatinib) including patients who received a chemotherapy line before TKI treatment. Samples have to be drawn before the patient starts a new treatment,
- Patients have to sign the informed consent of the study
- Patients aged ≥ 18 years.
Exclusion Criteria:
- Patients progressing to third generation EGFR TKIs (e.g. Osimertinib (TKI))
- No possibility of venipuncture.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: Kohorte
- Tidsperspektiver: Fremadrettet
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
---|---|
Patients with T790M mutation
Patient who has progressed to Tyrosin Kinase inhibitors and has the mutation of the gen T790M
|
Patients that received Tyrosin Kinase inhibitors and progressed
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Assess the agreement between qualitative methodologies
Tidsramme: At 12 months from the first inclusion
|
To evaluate the agreement performance of different methodologies available in Spain for T790M identification in circulating-free DNA isolated from blood collected at the time of progression on a first or second generation TKI
|
At 12 months from the first inclusion
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Cost of the different methodologies
Tidsramme: At 12 months from the first inclusion
|
To compare the cost of the different methodologies
|
At 12 months from the first inclusion
|
Specificity and sensitivity of each cfDNA method
Tidsramme: At 12 months from the first inclusion
|
To estimate the specificity and sensitivity of each cfDNA method.
|
At 12 months from the first inclusion
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Turnaround time of different methodologies
Tidsramme: At 12 months from the first inclusion
|
To compare turnaround time of the different methodologies
|
At 12 months from the first inclusion
|
Ease of use of different methodologies
Tidsramme: At 12 months from the first inclusion
|
To compare the ease of use of the different methodologies
|
At 12 months from the first inclusion
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Mariano Provencio, PhD, Hospital Puerta del Hierro
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- GECP 17/03_RING
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med NSCLC trin IV
-
Fondazione Policlinico Universitario Agostino Gemelli...Afsluttet
-
Niguarda HospitalUniversity of Turin, Italy; Fondazione del Piemonte per l'OncologiaAfsluttet
-
Fundación GECPAktiv, ikke rekrutterendeNSCLC | Lungekræft | NSCLC trin IV | NSCLC trin IIIBSpanien
-
Guangzhou Institute of Respiratory DiseaseIkke rekrutterer endnu
-
Mylan Pharmaceuticals IncAfsluttetNSCLC trin IVKalkun, Taiwan, Vietnam, Kroatien, Indien, Den Russiske Føderation, Spanien, Ungarn, Bosnien-Hercegovina, Ukraine, Polen, Rumænien, Hviderusland, Bulgarien, Georgien, Italien, Filippinerne
-
Instituto do Cancer do Estado de São PauloUkendt
-
Microbio Co LtdRekruttering
-
The Netherlands Cancer InstituteBristol-Myers SquibbAfsluttet
-
Fudan UniversityUkendt
-
KangLaiTe USAAfsluttetStage IV NSCLCForenede Stater
Kliniske forsøg med Tirosin Kinase Inhibitors
-
China-Japan Friendship HospitalIkke rekrutterer endnuKronisk obstruktiv lungesygdom
-
Infinity Pharmaceuticals, Inc.AfsluttetPrimær myelofibrose | Fibrose, knoglemarvForenede Stater
-
Merck Sharp & Dohme LLCAfsluttetMyelodysplastiske syndromer | Kronisk lymfatisk leukæmi | Leukæmi, lymfoblastisk, akut, T-celle | Myelogen leukæmi
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)RekrutteringDiffust storcellet B-celle lymfom | Tilbagevendende kappecellelymfom | Tilbagevendende marginalzone lymfom | Refraktær B-celle non-Hodgkin lymfom | Tilbagevendende B-celle non-Hodgkin lymfom | Refractory Mantle Cell Lymfom | Tilbagevendende follikulært lymfom | Refraktært follikulært lymfom | Tilbagevendende... og andre forholdForenede Stater
-
Merck Sharp & Dohme LLCAfsluttetAvanceret brystkræft | Andre faste tumorer
-
Genentech, Inc.National Cancer Institute (NCI); Sidney Kimmel Comprehensive Cancer Center...AfsluttetUspecificeret fast tumor hos voksne, protokolspecifik
-
Sahlgrenska University Hospital, SwedenAlbireoAfsluttet
-
Merck Sharp & Dohme LLCAfsluttetMyelodysplastiske syndromer | Leukæmi | Blast krise | Leukæmi, lymfocytisk | Leukæmi, Myeloid, Kronisk
-
National Cancer Institute (NCI)AfsluttetTilbagevendende gastrisk karcinom | Adenocarcinom i den gastroøsofageale forbindelse | Diffust gastrisk adenocarcinom | Gastrisk tarmtype Adenocarcinom | Gastrisk blandet adenokarcinomForenede Stater, Canada
-
University of Colorado, DenverThe Leukemia and Lymphoma SocietyAfsluttetTilbagevendende akut myeloid leukæmi hos voksne | Voksen akut myeloid leukæmi i remissionForenede Stater